Patient-derived Organoids of Lung Cancer to Test Drug Response
Recruiting · NCT03979170 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Geneva
View the official record on ClinicalTrials.gov →Interventions studied
Lung tumor resection
What this trial is about
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically proven lung cancer
- Age ≥ 18
- Written informed and signed consent
- Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
Exclusion criteria
- Less than 18 years of age
- Not able to give informed consent (language, intellectual capacities, etc.)
- Not accessible to biopsy and/or surgery sample
- Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
Where it is running
1 location listed.
- Geneva University Hospitals - Geneva, Switzerland